697305-62-7

Basic information

• Product Name: 1-(2-chloro-5-nitrophenyl)-N,N-dimethylmethanamine
• Synonyms: 1-(2-chloro-5-nitrophenyl)-N,N-dimethylmethanamine
• CAS NO: 697305-62-7
• Molecular Weight: 214.652
• Mol File: 697305-62-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(2-chloro-5-nitrophenyl)-N,N-dimethylmethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-chloro-5-nitrophenyl)-N,N-dimethylmethanamine(697305-62-7)
• EPA Substance Registry System: 1-(2-chloro-5-nitrophenyl)-N,N-dimethylmethanamine(697305-62-7)

Safety Data

• Hazardous Substances Data: 697305-62-7(Hazardous Substances Data)

Upstream product

• 60587-79-3 N,N-dimethyl-2-chloro-5-nitrobenzamide 
• 124-40-3 dimethyl amine 
• 6361-21-3 2-chloro-5-nitrobenzaldehyde 

Downstream Products

• 697305-72-9 4-chloro-3-((dimethylamino)methyl)aniline 
• 1446113-42-3 N-(4-chloro-3-((dimethylamino)methyl)phenyl)-6-methyl-5-nitroisoquinolin-1-amine 
• 1446113-43-4 N¹-(4-chloro-3-((dimethylamino)methyl)phenyl)-6-methylisoquinoline-1,5-diamine 
• 1446112-11-3 4-amino-N-(1-((4-chloro-3-((dimethylamino)methyl)phenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide 

Relevant articles and documents

THIENO[3,2-D]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

QUINAZOLINE DERIVATIVES FOR USE AGAINST CANCER

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt, solvate or pro-drug thereof, wherein each of p, R1, q, R2, R3, R4, R5, Ring A, X1, R6, r and R7 has any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders or in the treatment of disease states associated with angiogenesis and/or vascular permeability.